The "Gliomark" Project
Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography (GLIOMARK)
The objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer Tomography (SPECT).
The outcome of GLIOMARK is a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT.
Gliomas are recognized as a rare tumor disease with poor prognosis. Often computer tomography or magnetic resonance imaging is unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. Our kit employs TTF/SPECT and enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 673737.
The concept of this project was based on the innovative research work by Dr. Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina and University Hospital of Ioannina) and his group over the last decade.
- For a full list of beneficiaries see: http://ec.europa.eu/easme/en/sme-instrument-beneficiaries
- For press release see: http://cordis.europa.eu/project/rcn/198240_en.html
For more information about GLIOMARK please visit the project’s newly released website: